Results 171 to 180 of about 85,599,609 (253)

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19. [PDF]

Diabetes Metab J, 2021
Rhee SY, Lee J, Nam H, Kyoung DS, Shin DW, Kim DJ.   +5 more
europepmc   +1 more source

Role of glucagon in metabolic diseases

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Currently, diabetes is defined as “a chronic hyperglycemic state resulting from the absolute or relative insufficiency of insulin action,” emphasizing its characterization as an insulin‐related disease. However, glucagon dysregulation should also play a critical role in the pathophysiology of type 2 diabetes.
Tadahiro Kitamura, Yoko Tabei, Masaki Kobayashi   +2 more
wiley   +1 more source

Sitagliptin, a DPP-4 Inhibitor, Effectively Promotes the Healing of Diabetic Foot Ulcer: A Randomized Controlled Trial. [PDF]

J Diabetes
Gao W, Chen D, He H, Jiang N, Chen L, Ran X.   +5 more
europepmc   +1 more source

Temporal distribution of acute kidney injury–related hospitalizations after initiation of sodium–glucose cotransporter 2 inhibitors: A nationwide claims database analysis in older adults with an independent complementary single‐center eGFR analysis

Journal of Diabetes Investigation, EarlyView.
Among 190 older adults who experienced AKI‐related hospitalization after SGLT2 inhibitor initiation, 31.1% were hospitalized within 30 days. In an independent single‐center cohort, sustained early eGFR decline was associated with older age and use of one or two triple‐whammy‐related drug classes.
Kazuya Hiura, Ayana Tatsuno, Yamato Noto, Ryosuke Wakamatsu, Masayuki Sakunami, Ryu Kobayashi, Miki Yamashita   +6 more
wiley   +1 more source

DPP-4 inhibitor linagliptin modulates myocardial metabolism in a model of coronary artery disease. [PDF]

JTCVS Open
Muir KC, Harris DD, Stone C, Kanuparthy M, Hamze J, Sellke FW.   +5 more
europepmc   +1 more source

Frailty and low body mass index as key determinants of sodium‐glucose cotransporter 2 inhibitor‐specific adverse event‐related discontinuation in adults aged ≥75 years: A multicenter real‐world retrospective cohort study

Journal of Diabetes Investigation, EarlyView.
Among Japanese adults aged ≥75 years newly initiating SGLT2 inhibitors, SGLT2 inhibitor–specific adverse event‐related discontinuation occurred in 9.1% within 180 days. Frailty and low BMI, rather than chronological age, were the key predictors, highlighting the importance of assessing physiological reserve before treatment initiation.
Taisuke Uchida, Hiroaki Ueno, Ayaka Konagata, Hiroki Nabekura, Yuki Kikuchi, Takumi Beppu, Akari Sekishima, Hirotaka Sekishima, Takayuki Nakamura, Fumiko Kogo, Yudai Uehira, Yuri Tanaka, Hideki Yamaguchi, Kazuya Shimoda   +13 more
wiley   +1 more source

Clinical Outcomes with the Use of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Among Patients with Diabetes Mellitus and COVID-19: A Systematic Review of Observational Studies. [PDF]

J Clin Med
Alkhalifah SA, Alshahrani WA, Alshehri AM, Al Yami MS.   +3 more
europepmc   +1 more source

Dipeptidyl Peptidase (DPP)-4 Inhibitor Impairs the Outcomes of Patients with Type 2 Diabetes Mellitus After Curative Resection for Colorectal Cancer. [PDF]

Cancer Res Commun, 2021
Saito A, Kitayama J, Horie H, Koinuma K, Kawashima R, Ohzawa H, Yamaguchi H, Kawahira H, Mimura T, Lefor AK, Sata N.   +10 more
europepmc   +1 more source

Diabetes attenuates weight reduction‐mediated liver fibrosis regression in persons with morbid obesity

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims Weight loss by laparoscopic sleeve gastrectomy (LSG) compared to medical weight loss (low‐calorie diet: LCD) ameliorates diabetes and metabolic dysfunction‐associated steatotic liver disease (MASLD). We aimed to evaluate changes in liver pathology 1‐year after LSG and their associations with metabolic factors in Japanese participants with
Daiki Matsubara, Yumie Takeshita, Masahiro Mori, Yujiro Nakano, Kenichi Harada, Noboru Takata, Kengo Hayashi, Hideki Moriyama, Noriyuki Inaki, Masao Honda, Taro Yamashita, Toshinari Takamura   +11 more
wiley   +1 more source

Acute Pancreatitis After Initiating Dulaglutide in a Patient Previously Treated With a DPP-4 Inhibitor: Case Report From Palestine. [PDF]

Case Rep Gastrointest Med
Nasser A, Ladadweh H, Madia R, Dalashi A, Wahdan A, Alawi A.   +5 more
europepmc   +1 more source